Non-HIV-infected patients with Pneumocystis pneumonia in the intensive care unit: A bicentric, retrospective study focused on predictive factors of in-hospital mortality
- PMID: 35001555
- PMCID: PMC9060091
- DOI: 10.1111/crj.13463
Non-HIV-infected patients with Pneumocystis pneumonia in the intensive care unit: A bicentric, retrospective study focused on predictive factors of in-hospital mortality
Abstract
Background: The incidence of Pneumocystis pneumonia (PCP) among patients without human immunodeficiency virus (HIV) infection continues to increase. Here, we identified potential risk factors for in-hospital mortality among HIV-negative patients with PCP admitted to the intensive care unit (ICU).
Methods: We retrospectively analyzed medical records of 154 non-HIV-infected PCP patients admitted to the ICU at Peking Union Medical College Hospital (PUMCH) and China-Japan Friendship Hospital (CJFH) from October 2012 to July 2020. Clinical characteristics were examined, and factors related to in-hospital mortality were analyzed.
Results: A total of 154 patients were enrolled in our study. Overall, the in-hospital mortality rate was 65.6%. The univariate analysis indicated that nonsurvivors were older (58 vs. 52 years, P = 0.021), were more likely to use high-dose steroids (≥1 mg/kg/day prednisone equivalent, 39.62% vs. 55.34%, P = 0.047), receive caspofungin during hospitalization (44.6% vs. 28.3%, P = 0.049), require invasive ventilation (83.2% vs. 47.2%, P < 0.001), develop shock during hospitalization (61.4% vs. 20.8%, P < 0.001), and develop pneumomediastinum (21.8% vs. 47.2%, P = 0.001) and had higher Acute Physiology and Chronic Health Evaluation (APACHE) II scores on ICU admission (20.32 vs. 17.39, P = 0.003), lower lymphocyte counts (430 vs. 570 cells/μl, P = 0.014), and lower PaO2/FiO2 values (mmHg) on admission (108 vs. 147, P = 0.001). Multivariate analysis showed that age (odds ratio [OR] 1.03; 95% confidence interval [CI] 1.00-1.06; P = 0.024), use of high-dose steroids (≥1 mg/kg/day prednisone equivalent) during hospitalization (OR 2.29; 95% CI 1.07-4.90; P = 0.034), and a low oxygenation index on admission (OR 0.99; 95% CI 0.99-1.00; P = 0.014) were associated with in-hospital mortality.
Conclusions: The mortality rate of non-HIV-infected patients with PCP was high, and predictive factors of a poor prognosis were advanced age, use of high-dose steroids (≥1 mg/kg/day prednisone equivalent) during hospitalization, and a low oxygenation index on admission. The use of caspofungin during hospitalization might have no contribution to the prognosis of non-HIV-infected patients with PCP in the ICU.
Keywords: HIV-negative (non-HIV); Pneumocystis pneumonia; mortality; prognostic factor.
© 2022 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
[Clinical features of acute respiratory failure due to pneumocystis pneumonia in non-HIV immunocompromised patients].Zhonghua Yi Xue Za Zhi. 2016 Oct 18;96(38):3057-3061. doi: 10.3760/cma.j.issn.0376-2491.2016.38.005. Zhonghua Yi Xue Za Zhi. 2016. PMID: 27784445 Chinese.
-
[Risk factors for death in elderly patients admitted to intensive care unit after elective abdominal surgery: a consecutive 5-year retrospective study].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Dec;33(12):1453-1458. doi: 10.3760/cma.j.cn121430-20210804-00118. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 35131012 Chinese.
-
Development and validation of tools for predicting the risk of death and ICU admission of non-HIV-infected patients with Pneumocystis jirovecii pneumonia.Front Public Health. 2022 Nov 8;10:972311. doi: 10.3389/fpubh.2022.972311. eCollection 2022. Front Public Health. 2022. PMID: 36424963 Free PMC article.
-
The changing epidemiology of HIV-infected patients in the intensive care unit.J Intensive Care Med. 2011 May-Jun;26(3):151-64. doi: 10.1177/0885066610387996. Epub 2011 Mar 24. J Intensive Care Med. 2011. PMID: 21436170 Review.
-
Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study.Br J Anaesth. 2012 Mar;108(3):452-9. doi: 10.1093/bja/aer449. Epub 2012 Jan 31. Br J Anaesth. 2012. PMID: 22298243 Review.
Cited by
-
Cotrimoxazole as a Preventative Intervention for Pneumocystis Pneumonia in Pemphigus Patients Treated with Rituximab: A Retrospective Study.Dermatol Ther (Heidelb). 2023 Jul;13(7):1561-1576. doi: 10.1007/s13555-023-00953-9. Epub 2023 Jun 15. Dermatol Ther (Heidelb). 2023. PMID: 37322166 Free PMC article.
-
Characterization of the Pneumocystis jirovecii and Pneumocystis murina phosphoglucomutases (Pgm2s): a potential target for Pneumocystis therapy.Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0075623. doi: 10.1128/aac.00756-23. Epub 2024 Jan 23. Antimicrob Agents Chemother. 2024. PMID: 38259086 Free PMC article.
-
Mortality of Pneumocystis jirovecii pneumonia in intensive care units: a post-hoc analysis of an international multicenter study by ESGCIP and EFISG.Ann Med. 2025 Dec;57(1):2511043. doi: 10.1080/07853890.2025.2511043. Epub 2025 Jun 14. Ann Med. 2025. PMID: 40515506 Free PMC article.
-
Supplementary Role of Immunological Indicators in the Diagnosis and Prognosis of Pneumocystis Pneumonia in Non-HIV Immunocompromised Patients.Infect Drug Resist. 2022 Aug 21;15:4675-4683. doi: 10.2147/IDR.S372427. eCollection 2022. Infect Drug Resist. 2022. PMID: 36034170 Free PMC article.
-
Inflammatory phenotypes and clinical outcomes amongst patients with presumed and confirmed Pneumocystis jirovecii pneumonia without underlying human immunodeficiency virus infection.Pathog Dis. 2025 Jan 30;83:ftaf005. doi: 10.1093/femspd/ftaf005. Pathog Dis. 2025. PMID: 40275495 Free PMC article.
References
-
- Antinori A, Coenen T, Costagiola D, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12(1):61‐64. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources